Zedoresertib not checked
Debiopharm International SA · Debio 0123
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III, Advanced Solid Tumor
- Main trialPhase 1/2
- “The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. The primary purpose of Phase 1 (Dose expansion) of the study is to assess the doses studied…”In the company’s words, NCT05765812 on ClinicalTrials.gov
- Other names
- Debio 0123
Other drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up2
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- Sep 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Sep 2028 | A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | |
| Phase 1Recruiting | Dec 2027 | Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026